首页 >
法规速递
-
Document: Respiporc Flu3 : EPAR - All Authorised presentations-2025/10/14
2025-10-15查看详情 > -
Document: EMA health threats plan - Annex 1: Acceleration of regulatory procedures during public health emergencies-2025/11/18
2025-11-19查看详情 > -
Page: Union list of critical medicines-2025/12/12
2025-12-15查看详情 > -
深化改革 强化监管 切实保障药品高水平安全-2026/1/27
2026-01-28查看详情 > -
Document: Draft guidance on the conduct of clinical trials during public health emergencies-2026/3/4
2026-03-05查看详情 > -
Document: Records of data processing activity for the Union Product Database-2026/4/1
2026-04-02查看详情 > -
Document: Highlights from the second expert panels and notified bodies workshop-2026/5/18
2026-05-19查看详情 > -
国家药监局关于医用透明质酸钠产品管理类别的公告（2022年第103号）-2022/11/14
2022-11-30查看详情 > -
国家药监局关于银黄含化滴丸和热炎宁合剂转换为非处方药的公告（2023年第75号）-2023/6/20
2023-06-21查看详情 > -
Draft Guidance: Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act-2023/12/6
2023-12-21查看详情 >
